The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines
Nutrients · 2024
DOI: 10.3390/nu16050705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Yuki Denda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-…. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms, Sesquiterpenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We previously established pancreatic cancer (PaCa) cell lines resistant to gemcitabine and found that the activity of nuclear factor κB (NF-κB) was enhanced upon the acquisition of gemcitabine resistance. Parthenolide, the main active ingredient in feverfew, has been reported to exhibit antitumor activity by suppressing the NF-κB signaling pathway in several types of cancers. However, the antitumor effect of parthenolide on gemcitabine-resistant PaCa has not been elucidated. Here, we confirmed that parthenolide significantly inhibits the proliferation of both gemcitabine-resistant and normal PaCa cells at concentrations of 10 µM and higher, and that the NF-κB activity is significantly inhibited, even by 1 µM parthenolide. In Matrigel invasion assays and angiogenesis assays, the invasive and angiogenic potentials were higher in gemcitabine-resistant than normal PaCa cells and were inhibited by a low concentration of parthenolide. Furthermore, Western blotting showed suppressed MRP1 expression in gemcitabine-resistant PaCa treated with a low parthenolide concentration. In a colony formation assay, the addition of 1 µM parthenolide improved the sensitivity of gemcitabine-resistant PaCa cell lines to gemcitabine. These results suggest that parthenolide may be used as a novel therapeutic agent for the treatment of gemcitabine-resistant PaCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
ORCID-Profile: Yoichi Matsuo, Mamoru Morimoto
Zitieren
APA
Denda, Y., Matsuo, Y., Sugita, S., Eguchi, Y., Nonoyama, K., Murase, H., Kato, T., Imafuji, H., Saito, K., Morimoto, M., Ogawa, R., Takahashi, H., Mitsui, A., Kimura, M., & Takiguchi, S. (2024). The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines. Nutrients. https://doi.org/10.3390/nu16050705
Vancouver
Denda Y, Matsuo Y, Sugita S, Eguchi Y, Nonoyama K, Murase H, et al. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines. Nutrients. 2024. doi:10.3390/nu16050705
BibTeX
@article{Denda2024,
author = {Denda, Yuki and Matsuo, Yoichi and Sugita, Saburo and Eguchi, Yuki and Nonoyama, Keisuke and Murase, Hiromichi and Kato, Tomokatsu and Imafuji, Hiroyuki and Saito, Kenta and Morimoto, Mamoru and Ogawa, Ryo and Takahashi, Hiroki and Mitsui, Akira and Kimura, Masahiro and Takiguchi, Shuji},
title = {The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16050705}
}
EUVIMED